Posts by: Jose Marques Lopes, PhD

News

Tocilizumab, an approved therapy for children and adults with systemic juvenile idiopathic arthritis, is effective in real-life setting and shows evidence of benefiting most patients, according to a study done ... Read more

March 12, 2018March 12, 2018

Psychotherapy Technique Treats Methotrexate Intolerance in JIA Patients, Study Reports

News

Use of a psychotherapy method effectively reduces symptoms of methotrexate (MTX) intolerance in patients with juvenile idiopathic arthritis (JIA), according to German researchers. The study, “Successful treatment of methotrexate ... Read more

February 12, 2018February 12, 2018

US Demand for Rheumatologists Will Outstrip Supply by 2030, Studies Show

News

U.S. demand for rheumatologists will greatly surpass the projected growth of the rheumatology workforce over the next 12 years, two studies show. Overall, the studies point to an increasingly ... Read more

January 26, 2018January 26, 2018

Parents Concerned About Treatment Side Effects, Safety in Children with Juvenile Idiopathic Arthritis, Study Finds

News

A treatment’s long-term safety and the impact of its side effects on quality of life are the top concerns of parents with children who have juvenile idiopathic arthritis (JIA), ... Read more

January 24, 2018January 24, 2018

Riemser Boosts Global Profile with New JA Therapies in Canada, Great Britain

News

Canadian government approval of Aristospan (triamcinolone hexacetonide) to treat juvenile arthritis reinforces the global expansion efforts of Germany’s Riemser Pharma, which recently acquired the U.K. distribution rights for Jylamvo (methotrexate). Jylamvo ... Read more

January 10, 2018January 10, 2018

Adalimumab Improves Eye Inflammation of Children with Juvenile Arthritis, Phase 2/3 Trial Shows

News

Adalimumab improves the eye inflammation of children with early-onset juvenile idiopathic arthritis, a Phase 2/3 clinical trial shows. The study, published in the Annals of the Rheumatic Diseases, is titled ... Read more

October 4, 2017October 4, 2017

Disease Duration, Category May Help Predict Response to Enbrel in Juvenile Idiopathic Arthritis Patients

News

The category and duration of disease in juvenile idiopathic arthritis (JIA) could help predict whether treatment with Enbrel (etanercept) in patients without systemic manifestations will be effective, a new study ... Read more

Posts by: Jose Marques Lopes, PhD

Jose Marques Lopes, PhD

Tocilizumab Seen to Benefit Most Systemic JIA Patients in Real-life Setting, Study Shows

Psychotherapy Technique Treats Methotrexate Intolerance in JIA Patients, Study Reports

US Demand for Rheumatologists Will Outstrip Supply by 2030, Studies Show

Parents Concerned About Treatment Side Effects, Safety in Children with Juvenile Idiopathic Arthritis, Study Finds

Riemser Boosts Global Profile with New JA Therapies in Canada, Great Britain

Adalimumab Improves Eye Inflammation of Children with Juvenile Arthritis, Phase 2/3 Trial Shows

Disease Duration, Category May Help Predict Response to Enbrel in Juvenile Idiopathic Arthritis Patients

Pin It on Pinterest